Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
F0434 is a Merck KGaA fixed-dose oral combination of **gabapentin**, **thiamine**, and **cyanocobalamin** developed for neuropathic pain associated with diabetic peripheral neuropathy. Gabapentin binds voltage-dependent calcium-channel alpha-2/delta auxiliary subunits, reducing excitatory neurotransmission, while thiamine and cyanocobalamin provide B-vitamin support relevant to peripheral nerve metabolism and myelin function. The F0434-labelled Phase 3 trial in chronic distal diabetic polyneuropathy was completed; the trial record's brief summary inconsistently calls the product \"F0343,\" but its official title and intervention identify F0434. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01263132))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gabapentin + thiamine + cyanocobalamin.